Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2025Annals of Case ReportsOpen Access

CLL Management: Towards an MRD Guided Therapy

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

This review discusses MRD's role in treatment response and decision-making in CLL, highlighting immunophenotypic techniques.

Key Points

  • Undetectable MRD after treatment correlates with better outcomes in patients with CLL, enhancing treatment strategies and planning.
  • MRD assessment plays a critical role in risk stratification and treatment management, factoring into therapy choices and intensity.
  • The most common method for MRD detection in CLL is multicolor flow cytometry, crucial for evaluating disease status in peripheral blood.
  • Current clinical trial data on optimal assays for MRD in CLL is limited, indicating room for further research and validation.

Cite This Study

A 2025 study studied this question.

synapsesocial.com/papers/68af707c7567bf4f94fec5bbhttps://doi.org/10.29011/2574-7754.102369
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Role of Minimal Residual Disease (MRD) in Predicting Relapse in Acute Leukemia2025
  2. 2Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  3. 3Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges2025 · 6 citations
  4. 4Complexities of MRD Assays in ALL: A Guide for the Practicing Clinician2025
  5. 5Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights2025